ADC Therapeutics stock falls after LOTIS-7 trial update

Investing.com -- ADC Therapeutics SA (NYSE:ADCT) stock fell 22% Wednesday after the company released updated data from its LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA in combination with the ...

Foresight Diagnostics Announces Multiple Presentations in Lymphoma Featuring PhasED-Seq™ Ultrasensitive MRD Analysis at the upcoming ASH Annual Meeting

Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ ...
The Malaysian Reserve

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in ...

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 ...
Le Lézard

New Signateratm Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Natera, Inc. , a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking ...
TipRanks on MSN

ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma

ADC Therapeutics (ADCT) announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of Zynlonta ...
TipRanks on MSN

Antengene’s XPOVIO® Gains New Approvals in Hong Kong

The latest update is out from Antengene Corporation Limited ( ($HK:6996) ). Antengene Corporation Limited announced that the Hong Kong Department ...
Malaysia Sun

XPOVIO Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma

XPOVIO (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), ...
Fred Hutchinson Cancer Center

For many blood cancer patients, CAR T-cell therapy is game-changing

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

Rutgers Cancer Institute and RWJBarnabas Health to Showcase Practice-Changing Blood Cancer Research at the 67th American Society of Hematology Annual Meeting and Exposition

RWJBarnabas Health's commitment to enhancing access to care includes a transformative partnership with Rutgers University, including the Rutgers Cancer Institute -- the state's only NCI-designated ...

CytoAgents Announces Poster Presentation of New CTO1681 Clinical Data at the 67th American Society of Hematology Annual Meeting

CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, a novel, steroid sparing inhibitor of prostaglandin mediated inflammation, announced today that preliminary safety data ...
ConsumerAffairs

Tattoo ink races into lymph nodes, kills immune cells and alters vaccine responses, study finds

Mouse research shows tattoo pigments move into lymph nodes within minutes and persist for months Ink triggered immune-cell ...
MedPage Today

Future Directions in DLBCL: Innovations in the Frontline and Relapsed Settings

Ahead of the upcoming American Society of Hematology (ASH) annual meeting, Alex Niu, MD, of Roswell Park Comprehensive Cancer ...